Novartis/Schering AG oral angiogenesis inhibitor PTK/ZK completes enrollment for key Phase III metastatic colorectal cancer trial.: An article from: BIOTECH Patent News

This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on May 1, 2004. The length of the article is 757 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Novartis/Schering AG oral angiogenesis inhibitor PTK/ZK completes enrollment for key Phase III metastatic colorectal cancer trial.
Publication:BIOTECH Patent News (Newsletter)
Date: May 1, 2004
Publisher: Biotech Patent News
Volume: 18 Issue: 5

Distributed by Thomson Gale